Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial.
Vakaet V, Van Hulle H, Van de Vijver K, Hilderson I, Naert E, De Neve W, Vandorpe J, Hendrix A, Göker M, Depypere H, Vergauwen G, Van den Broecke R, De Visschere P, Braems G, Vandecasteele K, Denys H, Veldeman L. Vakaet V, et al. Among authors: vandecasteele k. Breast. 2022 Apr;62:10-15. doi: 10.1016/j.breast.2022.01.010. Epub 2022 Jan 20. Breast. 2022. PMID: 35091184 Free PMC article. Clinical Trial.
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.
Vandecasteele K, De Neve W, De Gersem W, Delrue L, Paelinck L, Makar A, Fonteyne V, De Wagter C, Villeirs G, De Meerleer G. Vandecasteele K, et al. Strahlenther Onkol. 2009 Dec;185(12):799-807. doi: 10.1007/s00066-009-1986-8. Strahlenther Onkol. 2009. PMID: 20013089
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W. De Meerleer G, et al. Among authors: vandecasteele k. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20421155
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.
Vandecasteele K, Delrue L, Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, De Meerleer G. Vandecasteele K, et al. Int J Gynecol Cancer. 2012 May;22(4):630-7. doi: 10.1097/IGC.0b013e3182428925. Int J Gynecol Cancer. 2012. PMID: 22237382
Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.
Vandecasteele K, Makar A, Van den Broecke R, Delrue L, Denys H, Lambein K, Lambert B, van Eijkeren M, Tummers P, De Meerleer G. Vandecasteele K, et al. Strahlenther Onkol. 2012 Jul;188(7):576-81. doi: 10.1007/s00066-012-0097-0. Epub 2012 Apr 19. Strahlenther Onkol. 2012. PMID: 22526231 Clinical Trial.
69 results